Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies (2018)
Source: Advances in rheumatology. Unidade: FM
Subjects: MIOSITE, ANTICORPOS MONOCLONAIS
ABNT
SOUZA, Fernando Henrique Carlos de et al. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Advances in rheumatology, v. 58, 2018Tradução . . Disponível em: https://doi.org/10.1186/s42358-018-0030-z. Acesso em: 01 set. 2024.APA
Souza, F. H. C. de, Miossi, R., Moraes, J. C. B. de, Bonfá, E. S. D. de O., & Shinjo, S. K. (2018). Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Advances in rheumatology, 58. doi:10.1186/s42358-018-0030-zNLM
Souza FHC de, Miossi R, Moraes JCB de, Bonfá ESD de O, Shinjo SK. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies [Internet]. Advances in rheumatology. 2018 ; 58[citado 2024 set. 01 ] Available from: https://doi.org/10.1186/s42358-018-0030-zVancouver
Souza FHC de, Miossi R, Moraes JCB de, Bonfá ESD de O, Shinjo SK. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies [Internet]. Advances in rheumatology. 2018 ; 58[citado 2024 set. 01 ] Available from: https://doi.org/10.1186/s42358-018-0030-z